Christopher Thanos

Christopher Thanos has extensive work experience in the biotechnology industry. Christopher is currently the President, CEO, and Cofounder of Actym Therapeutics, a biotechnology company focused on developing novel immuno-oncology therapies for cancer treatment. Prior to their role at Actym Therapeutics, Christopher served as a Senior Director and Director at Halozyme Therapeutics, where they were involved in biotherapeutics discovery and the development of new molecular entities. Christopher also held the position of Director of Protein Engineering at Sutro Biopharma. Additionally, Christopher played a crucial role as a Cofounder of Catalyst Biosciences, where they established initial operations, raised venture capital, and contributed to the invention of various therapeutic technologies and products. Christopher has also worked as a National Cancer Institute Postdoctoral Fellow at both UCSF and Sunesis Pharmaceuticals, conducting research on protein hot spots and small molecules bound to proteins.

Christopher Thanos received their Ph.D. in Molecular Biology and Biochemistry from UCLA, completing their studies from 1994 to 1999.